Artica Therapeutics uses covalent chemistry to develop orally bioavailable small‑molecule inhibitors that achieve antibody‑like potency and selectivity for autoimmune and inflammatory diseases. By forming irreversible bonds with disease‑relevant proteins, its “insurmountable” drugs maintain target engagement even under high stimulation, offering a convenient oral alternative to injectable biologics.
Funding
$12.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
2OSLFounders
Product
Problem
Patients with severe autoimmune and inflammatory diseases rely on injectable antibody therapies, which are costly, require frequent administration, and often cannot achieve sufficient target engagement for protein‑protein interaction targets.
Solution
Artica Therapeutics applies covalent chemistry to create orally bioavailable small‑molecule inhibitors that mimic the potency and selectivity of antibodies. By forming irreversible bonds with disease‑relevant proteins, these compounds maintain activity even under high disease‑protein stimulation, providing “insurmountable” target engagement. The platform enables rapid design and optimization of candidates against clinically validated immunology targets that are traditionally addressed with biologics. Oral delivery improves patient convenience and adherence while reducing the logistical and manufacturing complexities associated with injectable biologics. Artica’s approach aims to deliver differentiated therapies for unmet needs in autoimmune and inflammatory disorders.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing therapies for autoimmune and inflammatory diseases that require high target engagement and oral administration.
Features
- Covalent binding mechanism that ensures irreversible target engagement and sustained inhibition
- Oral formulation of small‑molecule inhibitors, eliminating the need for injections
- Design focus on disrupting protein‑protein interactions traditionally addressed by antibodies
- High selectivity achieved through structure‑based chemistry and rapid candidate optimization
- “Insurmountable” pharmacology: activity retained despite excessive disease‑protein stimulation
- Platform capable of advancing multiple autoimmune and inflammatory indications in parallel